Your browser doesn't support javascript.
loading
Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.
Muir, Roshell; Metcalf, Talibah; Fourati, Slim; Bartsch, Yannic; Kyosiimire-Lugemwa, Jacqueline; Canderan, Glenda; Alter, Galit; Muyanja, Enoch; Okech, Brenda; Namatovu, Teddy; Namara, Irene; Namuniina, Annemarie; Ssetaala, Ali; Mpendo, Juliet; Nanvubya, Annet; Kitandwe, Paul Kato; Bagaya, Bernard S; Kiwanuka, Noah; Nassuna, Jacent; Biribawa, Victoria Menya; Elliott, Alison M; de Dood, Claudia J; Senyonga, William; Balungi, Priscilla; Kaleebu, Pontiano; Mayanja, Yunia; Odongo, Matthew; Connors, Jennifer; Fast, Pat; Price, Matt A; Corstjens, Paul L A M; van Dam, Govert J; Kamali, Anatoli; Sekaly, Rafick Pierre; Haddad, Elias K.
Affiliation
  • Muir R; Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
  • Metcalf T; Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
  • Fourati S; PATRU, School of Medicine, Emory University, Atlanta, Georgia, United States of America.
  • Bartsch Y; Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, United States of America.
  • Kyosiimire-Lugemwa J; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Canderan G; Department of Medicine, Allergy and Immunology, University of Virginia, Charlottesville, Virginia, United States of America.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, United States of America.
  • Muyanja E; PATRU, School of Medicine, Emory University, Atlanta, Georgia, United States of America.
  • Okech B; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • Namatovu T; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • Namara I; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • Namuniina A; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • Ssetaala A; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • Mpendo J; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • Nanvubya A; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • Kitandwe PK; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • Bagaya BS; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Kiwanuka N; Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University, College of Health Sciences, Kampala, Uganda.
  • Nassuna J; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University, College of Health Sciences, Kampala, Uganda.
  • Biribawa VM; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University, College of Health Sciences, Kampala, Uganda.
  • Elliott AM; UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda.
  • de Dood CJ; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Senyonga W; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Balungi P; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.
  • Kaleebu P; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Mayanja Y; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Odongo M; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Connors J; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Fast P; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Price MA; Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
  • Corstjens PLAM; International AIDS Vaccine Initiative, New York, New York, United States of America.
  • van Dam GJ; Pediatric Infectious Diseases, Stanford University School of Medicine, Palo Alto, California, United States of America.
  • Kamali A; International AIDS Vaccine Initiative, New York, New York, United States of America.
  • Sekaly RP; Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California, United States of America.
  • Haddad EK; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.
PLoS Negl Trop Dis ; 17(7): e0011089, 2023 07.
Article de En | MEDLINE | ID: mdl-37406029
ABSTRACT
Schistosomiasis is a disease caused by parasitic flatworms of the Schistosoma spp., and is increasingly recognized to alter the immune system, and the potential to respond to vaccines. The impact of endemic infections on protective immunity is critical to inform vaccination strategies globally. We assessed the influence of Schistosoma mansoni worm burden on multiple host vaccine-related immune parameters in a Ugandan fishing cohort (n = 75) given three doses of a Hepatitis B (HepB) vaccine at baseline and multiple timepoints post-vaccination. We observed distinct differences in immune responses in instances of higher worm burden, compared to low worm burden or non-infected. Concentrations of pre-vaccination serum schistosome-specific circulating anodic antigen (CAA), linked to worm burden, showed a significant bimodal distribution associated with HepB titers, which was lower in individuals with higher CAA values at month 7 post-vaccination (M7). Comparative chemokine/cytokine responses revealed significant upregulation of CCL19, CXCL9 and CCL17 known to be involved in T cell activation and recruitment, in higher CAA individuals, and CCL17 correlated negatively with HepB titers at month 12 post-vaccination. We show that HepB-specific CD4+ T cell memory responses correlated positively with HepB titers at M7. We further established that those participants with high CAA had significantly lower frequencies of circulating T follicular helper (cTfh) subpopulations pre- and post-vaccination, but higher regulatory T cells (Tregs) post-vaccination, suggesting changes in the immune microenvironment in high CAA could favor Treg recruitment and activation. Additionally, we found that changes in the levels of innate-related cytokines/chemokines CXCL10, IL-1ß, and CCL26, involved in driving T helper responses, were associated with increasing CAA concentration. This study provides further insight on pre-vaccination host responses to Schistosoma worm burden which will support our understanding of vaccine responses altered by pathogenic host immune mechanisms and memory function and explain abrogated vaccine responses in communities with endemic infections.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Schistosomiase à Schistosoma mansoni Limites: Animals Langue: En Journal: PLoS Negl Trop Dis Sujet du journal: MEDICINA TROPICAL Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Schistosomiase à Schistosoma mansoni Limites: Animals Langue: En Journal: PLoS Negl Trop Dis Sujet du journal: MEDICINA TROPICAL Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique